JP2008500366A5 - - Google Patents

Download PDF

Info

Publication number
JP2008500366A5
JP2008500366A5 JP2007515355A JP2007515355A JP2008500366A5 JP 2008500366 A5 JP2008500366 A5 JP 2008500366A5 JP 2007515355 A JP2007515355 A JP 2007515355A JP 2007515355 A JP2007515355 A JP 2007515355A JP 2008500366 A5 JP2008500366 A5 JP 2008500366A5
Authority
JP
Japan
Prior art keywords
moiety
aryl
heteroaryl
heterocyclic
alicyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007515355A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008500366A (ja
JP5149001B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/018603 external-priority patent/WO2006001967A2/en
Publication of JP2008500366A publication Critical patent/JP2008500366A/ja
Publication of JP2008500366A5 publication Critical patent/JP2008500366A5/ja
Application granted granted Critical
Publication of JP5149001B2 publication Critical patent/JP5149001B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007515355A 2004-05-25 2005-05-25 癌の処置におけるマイグラスタチンアナログ Expired - Fee Related JP5149001B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57411404P 2004-05-25 2004-05-25
US60/574,114 2004-05-25
PCT/US2005/018603 WO2006001967A2 (en) 2004-05-25 2005-05-25 Migrastatin analogs in the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008136097A Division JP2008273981A (ja) 2004-05-25 2008-05-23 癌の処置におけるマイグラスタチンアナログ

Publications (3)

Publication Number Publication Date
JP2008500366A JP2008500366A (ja) 2008-01-10
JP2008500366A5 true JP2008500366A5 (enExample) 2008-07-10
JP5149001B2 JP5149001B2 (ja) 2013-02-20

Family

ID=35355865

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007515355A Expired - Fee Related JP5149001B2 (ja) 2004-05-25 2005-05-25 癌の処置におけるマイグラスタチンアナログ
JP2008136097A Pending JP2008273981A (ja) 2004-05-25 2008-05-23 癌の処置におけるマイグラスタチンアナログ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008136097A Pending JP2008273981A (ja) 2004-05-25 2008-05-23 癌の処置におけるマイグラスタチンアナログ

Country Status (3)

Country Link
US (1) US8957056B2 (enExample)
JP (2) JP5149001B2 (enExample)
WO (1) WO2006001967A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4719671B2 (ja) 2003-03-28 2011-07-06 コーネル・リサーチ・ファンデーション・インコーポレイテッド ミグラスタチンアナログ組成物およびその使用
US8957056B2 (en) 2004-05-25 2015-02-17 Sloan-Kettering Instiute For Cancer Research Migrastatin analogs in the treatment of cancer
US8188141B2 (en) * 2004-09-23 2012-05-29 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
CN102580086A (zh) * 2006-05-22 2012-07-18 埃克斯生物科技公司 使用抗IL-1α抗体治疗癌症
US20080312317A1 (en) * 2007-04-12 2008-12-18 Eisai R&D Management Co., Ltd. 12 membered-ring macrolactam derivatives
CN101918036A (zh) * 2007-11-21 2010-12-15 康奈尔大学 抑制肌成束蛋白的方法
HUE029003T2 (en) 2008-05-30 2017-01-30 Xbiotech Inc IL-1 alpha antibodies
US20110306563A1 (en) * 2008-12-17 2011-12-15 Sanofi Macrolactone derivatives, method for the production thereof and use thereof for the treatment of cancer
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
CN102946904A (zh) 2010-06-18 2013-02-27 埃克斯生物科技公司 关节炎治疗
PH12013500316A1 (en) 2010-08-23 2016-09-02 Janssen Biotech Inc Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
EP2694107B1 (en) 2011-04-01 2018-08-22 XBiotech, Inc Treatment for dermatological pathologies
AU2012239977B9 (en) * 2011-04-07 2016-11-17 Sloan-Kettering Institute For Cancer Research Migrastatins and uses thereof
WO2013013240A2 (en) * 2011-07-21 2013-01-24 Theracrine, Inc. Macrocyclic compounds and related compositons and methods of use
PT2750709T (pt) 2011-09-23 2018-11-22 Xbiotech Inc Tratamento da caquexia
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
JP7145162B2 (ja) 2017-02-16 2022-09-30 ヤンセン バイオテク，インコーポレイテッド 化膿性汗腺炎の処置
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL66434C (enExample) 1946-12-06
FR1264032A (fr) 1960-05-06 1961-06-19 Rhone Poulenc Sa Acide cycloundecanecarboxylique
GB1036084A (en) 1962-02-23 1966-07-13 Upjohn Co Oxygenated cycloalkanes and the preparation thereof
NL302921A (enExample) 1963-01-21
DE2934683A1 (de) 1979-08-28 1981-03-12 Haarmann & Reimer Gmbh, 3450 Holzminden 3-methyl-cyclohexadecen-5-on-1, verfahren zu seiner herstellung und seine verwendung als riechstoff.
DE2934678A1 (de) 1979-08-28 1981-03-12 Haarmann & Reimer Gmbh, 3450 Holzminden Cyclopentadecen-8-on-1, verfahren zu seiner herstellung und seine verwendung als riechstoff
US4472435A (en) 1980-07-31 1984-09-18 Hoffman-La Roche Inc. Benzophenone derivatives useful in treating heart failure
JPS6156146A (ja) 1984-08-28 1986-03-20 Nippon Mining Co Ltd 大環状ケトンの製造方法
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
EP0374445A1 (fr) 1988-12-23 1990-06-27 Firmenich Sa Nouveaux composés cycliques oxygénés, leur utilisation à titre d'ingrédients parfumants, procédé pour leur préparation
JPH07138257A (ja) 1993-11-16 1995-05-30 Taisho Pharmaceut Co Ltd 骨吸収抑制物質ｂｒ−０４０及びｂｒ−０４２
AR043071A1 (es) 1997-10-31 2005-07-20 Abbott Lab Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
EP0976714A1 (en) 1998-07-06 2000-02-02 Quest International B.V. Addition of ketones to alkenes
SG80643A1 (en) 1998-09-03 2001-05-22 Givaudan Roure Int Methylcyclotetradec-5-en-1-ones
JP2000247949A (ja) 1999-02-26 2000-09-12 Eisai Co Ltd スルホンアミド含有インドール化合物
JP2001078793A (ja) 1999-09-10 2001-03-27 Nippon Kayaku Co Ltd 新規生理活性物質の醗酵法による製造法
JP2001081088A (ja) 1999-09-10 2001-03-27 Nippon Kayaku Co Ltd 新規生理活性物質ｎｋ３０４２４類縁体とそれらの製造法および用途
WO2001046451A1 (en) 1999-12-22 2001-06-28 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Migrastatin, process for producing the same and medicinal compositions
US6750047B2 (en) 2000-08-21 2004-06-15 Kosan Biosciences, Inc. Fermentation and purification of migrastatin and analog
US6660306B2 (en) 2000-10-12 2003-12-09 Mickey L. Peshoff Wound healing compound
TWI312681B (en) 2001-02-01 2009-08-01 Novel physiologically active substance
AU2002254822A1 (en) 2001-04-26 2002-11-11 Ecopia Biosciences Inc. Genes and proteins for the biosynthesis of polyketides
DE60216362T2 (de) 2001-06-08 2007-09-20 Takasago International Corp. Inhibitoren der Melaninherstellung und solche Inhibitoren enthaltende Hautpflegemittel
JP2003104967A (ja) 2001-09-28 2003-04-09 Takuma Sasaki ウロキナーゼ産生阻害剤、血管新生阻害剤、癌転移抑制剤および抗腫瘍剤
JP3973889B2 (ja) 2001-12-04 2007-09-12 株式会社ジャパンエナジー 大環状ケトン化合物の製造方法
JP4463682B2 (ja) 2002-07-23 2010-05-19 ソシエテ ド テクノロジー ミシュラン 補強構造体の非真直アンカーリングを備えたタイヤ
KR20050084224A (ko) 2002-12-09 2005-08-26 더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 야누스 티로신 키나제 3을 선택적으로 저해하는 방법
JP4337815B2 (ja) 2003-03-19 2009-09-30 宇部興産株式会社 ω−シアノアルデヒド化合物の製造法
US20070037783A1 (en) 2003-03-28 2007-02-15 Xin-Yun Huang Migrastatin analogs and uses thereof
JP4719671B2 (ja) * 2003-03-28 2011-07-06 コーネル・リサーチ・ファンデーション・インコーポレイテッド ミグラスタチンアナログ組成物およびその使用
WO2005019181A1 (en) 2003-08-19 2005-03-03 Cornell Research Foundation, Inc. Migrastatin analog cell migration inhibitors
US8957056B2 (en) 2004-05-25 2015-02-17 Sloan-Kettering Instiute For Cancer Research Migrastatin analogs in the treatment of cancer
US8188141B2 (en) 2004-09-23 2012-05-29 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
CN101918036A (zh) 2007-11-21 2010-12-15 康奈尔大学 抑制肌成束蛋白的方法

Similar Documents

Publication Publication Date Title
US20250120947A1 (en) Compounds and methods to sensitize cancer cells to cisplatin
ES2978534T3 (es) Análogos de éter de fosfolípidos como vehículos de fármacos contra el cáncer
AU2002210993B2 (en) Medicinal compositions for concominant use as anticancer agents
WO2025083472A2 (en) Protac compounds binding keap1 ubiquitin ligase for targeted protein degradation
JP2008523099A5 (enExample)
JP2008535902A5 (enExample)
ES2377975T3 (es) Composición medicinal que comprende un inhibidor de la HMG-CoA reductasa y un derivado de aminoalcohol como inmunodepresor
JP6002835B2 (ja) 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤
RU2011142750A (ru) Способ лечения путем применения комбинированной терапии
JP2015500209A5 (enExample)
JP2012528858A5 (enExample)
JP2006523233A5 (enExample)
ES2746105T3 (es) Profármacos de 5-aza-pirimidina sililada útiles para tratar el cáncer
JP2006508965A5 (enExample)
JP2006510658A5 (enExample)
JP2013504590A5 (enExample)
CN109956986A (zh) 肝递送吉西他滨前体药物核苷环磷酸酯化合物及应用
ES2701123T3 (es) Derivados de taxano solubles en agua y sus usos
JP2006521407A5 (enExample)
JP2013525290A5 (enExample)
RU2004111787A (ru) Ретиноидные агонисты (1), производные алкилмочевины
WO2022214937A1 (en) Substituted tetracyclic carboxylic acids, analogues thereof, and methods using same
JP5701387B2 (ja) ベルバミンのジカルボキシミド誘導体、その調製方法及び使用
JP2003535890A5 (enExample)
SK18332002A3 (sk) Farmaceutický prostriedok obsahujúci farmaceuticky prijateľný nosič alebo masťový základ a ako aktívnu prísadu derivát akryloyldistamycínu a inhibítor topoizomerázy I a II